文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤

个体化新抗原治疗mRNA-4157(V940)单用或联合帕博利珠单抗在1期KEYNOTE-603研究中的T细胞反应

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
PubMed 文献 · Cancer Discov · 2024-01-01

KEYNOTE-603是一项首次人体1期研究,评估mRNA-4157(靶向最多34个患者特异性肿瘤新抗原)在已切除非小细胞肺癌(A部分:1 mg mRNA-4157,n=4)或已切除皮肤黑色素瘤(D部分:1 mg mRNA-4157联合200 mg帕博利珠单抗,n=12)患者中的安全性和免疫原性。所有患者均发生至少1例治疗中出现的不良事件,未发生4/5级不良事件或剂量限制性毒性。mRNA-4157单药可诱导一致的新生和增强的针对靶向新抗原的T细胞反应;联合治疗后观察到持续的mRNA-4157诱导的新抗原特异性T细胞反应及细胞毒性CD8和CD4 T细胞扩增。

要点

  • 所有患者发生至少1例治疗中出现的不良事件,无4/5级不良事件或剂量限制性毒性。
  • mRNA-4157单药诱导一致的新生和增强的针对靶向新抗原的T细胞反应。
  • 联合帕博利珠单抗后观察到持续的新抗原特异性T细胞反应及细胞毒性CD8和CD4 T细胞扩增。

核心结论

  • mRNA-4157单用或联合帕博利珠单抗可诱导新生和增强的新抗原特异性T细胞反应,为后续开发提供机制性概念验证。

研究设计与样本

  • 首次人体1期KEYNOTE-603研究(NCT03313778),已切除非小细胞肺癌患者接受1 mg mRNA-4157单药(A部分,n=4),已切除皮肤黑色素瘤患者接受1 mg mRNA-4157联合200 mg帕博利珠单抗(D部分,n=12)。
  • 评估安全性、耐受性和免疫原性。

主要发现

  • 所有患者发生至少1例治疗中出现的不良事件,未发生4/5级不良事件或剂量限制性毒性。
  • mRNA-4157单药诱导一致的新生和增强的针对靶向新抗原的T细胞反应。
  • 联合治疗后观察到持续的mRNA-4157诱导的新抗原特异性T细胞反应及细胞毒性CD8和CD4 T细胞扩增。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens to induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of mRNA-4157 via characterization of T-cell responses to neoantigens from the first-in-human, phase 1, KEYNOTE-603 study (NCT03313778) in patients with resected non-small cell lung cancer (Part A: 1-mg mRNA-4157, n = 4) or resected cutaneous melanoma (Part D: 1-mg mRNA-4157 + 200-mg pembrolizumab, n = 12). Safety, tolerability, and immunogenicity were assessed. All patients experienced ≥1 treatment-emergent adverse event; there were no grade 4/5 adverse events or dose-limiting toxicities. mRNA-4157 alone induced consistent de novo and strengthened preexisting T-cell responses to targeted neoantigens. Following combination therapy, sustained mRNA-4157-induced neoantigen-specific T-cell responses and expansion of cytotoxic CD8 and CD4 T cells were observed. These findings show the potential of a novel mRNA individualized neoantigen therapy approach in oncology. Significance: The safety and immunogenicity results from this phase 1 study of mRNA-4157 as adjuvant monotherapy or combination therapy with pembrolizumab show generation of de novo and enhancement of existing neoantigen-specific T-cell responses and provide mechanistic proof of concept to support further development of mRNA-4157 for patients with resected solid tumors. See related commentary by Berraondo et al., p. 2021.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Gainor JF, Patel MR, Weber JS, et al. T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discov. 2024. PMID: 39115419. doi:10.1158/2159-8290.CD-24-0158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。